Sigrid Therapeutics Selected to Present Results from STAR Proof of Concept Trial at American Diabetes Association 80[th] Scientific Sessions
Stockholm, Sweden — June 8[th], 2020 — Sigrid Therapeutics (Sigrid) today announced that the Company’s STAR study results have been selected for presentation at the American Diabetes Associations 80[th] Scientific Session on June 12-16, 2020 in Chicago, Ilinois. The STAR study (clinicaltrials.org ID no. NCT03823027) was an open-label, single-arm, multicenter study with the primary objective of demonstrating a reduction in long term blood sugar, as measured by HbA1c, in prediabetics after 12 weeks of treatment. The results of the trial have the potential to impact patient care of prediabetics